Philips launches next generation wearable biosensor for early patient deterioration detection, including clinical surveillanc...
27 May 2020 - 12:00AM
Philips launches next generation wearable biosensor for early
patient deterioration detection, including clinical surveillance
for COVID-19
May 26, 2020
- Wireless wearable biosensor (Philips Biosensor BX100) receives
510(k) clearance from the FDA and CE mark to help monitor COVID-19
patients in hospital, with first install at OLVG Hospital in the
Netherlands
- Further enhances Philips portfolio of devices, software and
services for identifying patients at risk for deterioration while
limiting exposure to help improve staff and patient safety and
preserve valuable personal protective equipment
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced it has received 510(k) clearance from the U.S. Food and
Drug Administration (FDA) for its wearable biosensor (Philips
Biosensor BX100) to help manage confirmed and suspected COVID-19
patients in the hospital. The next generation wireless wearable
biosensor enhances clinical surveillance in the Philips patient
deterioration detection solution to help clinicians detect risk so
they can intervene earlier and help improve care for patients in
lower acuity care areas. The solution has already received CE mark,
and is currently in use with the first install at the OLVG Hospital
in the Netherlands to help manage the triage and clinical
surveillance of COVID-19 patients.
The Philips Biosensor BX100 is designed to address a new
approach to vital signs measurements, supporting surveillance of
higher acuity patients moving from intensive care units into lower
acuity general care areas of a hospital. The lightweight,
disposable biosensor is a 5-day, single-use wearable patch which
can be integrated with a scalable hub to monitor multiple patients
across multiple rooms. Built to incorporate into existing clinical
workflows for mobile viewing and notifications, the device requires
no cleaning or charging. The medical-grade wireless wearable
biosensor, intended for use by healthcare professionals on patients
18 years of age and older, adheres discreetly to the chest to
collect, store, measure and transmit respiratory rate and heart
rate every minute – the top two predictors of deterioration – as
well as contextual parameters such as posture, activity level and
ambulation.
OLVG, a top clinical, referral and training hospital in the
Netherlands is responding to the COVID-19 emergency situation by
remotely monitoring patients in isolation rooms who are diagnosed
or suspected of COVID, but don’t need ventilation. To meet the
hospital’s need to support COVID-19 patients in isolation, OLVG has
implemented Philips patient deterioration detection solution
comprised of data-driven intelligent analytics software (IntelliVue
GuardianSoftware) for early warning scoring, advanced patient
monitors (EarlyVue VS30), and the Philips Biosensor BX100 wearable
sensors.
“During this unprecedented time of COVID-19, the Philips
Biosensor BX100 helps provide rapid deployment for clinical
surveillance to help decrease risk of exposure of healthcare
workers while acquiring frequent patient vitals, and easing the
demand for personal protective equipment (PPE),” said Peter Ziese,
General Manager Monitoring and Analytics at Philips. “The biosensor
is an integral component in our Patient Deterioration Detection
solution which helps aid in the identification of the subtle signs
of deterioration in a patient’s condition at the point of care,
hours before a potential adverse event would occur.”
“With the help of this new biosensor, we can continuously and
remotely monitor patients, which is especially important on the
COVID-19 wards,” said Florian van der Hunnik, Chief Nursing
Information Officer and team leader of the COVID-19 ward at OLVG
Hospital in Amsterdam. “Because we cannot walk in and out of the
patient rooms without protective gear, we welcome this innovation
as it helps improve how we can do our jobs better.”
The Philips next generation wearable biosensor is part of the
Philips comprehensive portfolio of solutions to address patient
deterioration, supporting general care around the world with smart
clinical intelligence. For more information on how Philips is
addressing the Coronavirus globally, please visit the Philips
centralized COVID-19 hub.
For further information, please contact:
Kathy O’ReillyPhilips Global Press OfficeTel.: +1 978 221
8919E-mail: kathy.oreilly@philips.com Twitter:
@kathyoreilly
Pieter van MeerPhilips BeneluxTel.: +31 6 25 2690 65Email:
pieter.de.meer@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2019
sales of EUR 19.5 billion and employs approximately 81,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- Philips introduces Philips Biosensor BX100
- Philips Biosensor BX100
- SolutionDataFlowGraphic_Web700
- Philips Biosensor BX100
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Apr 2024 to May 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From May 2023 to May 2024